Drug Efflux Pump Expression in 50,000 Molecularly-Profiled Cancer Patients | Caris Life Sciences
Home / Research / Publications / Drug Efflux Pump Expression in 50,000 Molecularly-Profiled Cancer Patients

Publications

Drug Efflux Pump Expression in 50,000 Molecularly-Profiled Cancer Patients

Abstract

Background: The multidrug resistance (MDR) phenotype reduces the efficacy of various chemotherapies. MDR is linked to the overexpression of ATP-binding cassette (ABC) transporters in cancer cells, including P-glycoprotein (PGP/ABCB1), multidrug resistance protein (MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2). We assessed protein expression patterns of the drug efflux pumps across all tumor types for insight on how to exploit MDR status to circumvent treatment dilemmas.

Download Publication
Learn More
Name(Required)